Martin Keßler, CEO at Rentschler Biopharma Inc., met with Pharma's Almanac to talk about the new investment of the Rentschler Biopharma Manufacturing Center in the US, a new state-of-the-art facility with four 2,000-liter bioreactors, and two downstream suits.
